Category Archives: Indian Patent Law

India–EFTA trade talks may make medicines more expensive

MSF and civil society urge Swiss negotiators not to undermine the ‘pharmacy of the developing world’   Geneva/New Delhi, 22March 2017 – Asintellectual property (IP) negotiators from India andthe four countries from EFTA (European Free Trade Association) meeting New Delhi … Continue reading

Posted in Data Exclusivity, EFTA-India FTA, Evergreening, Patent, Sec 3 (d), Uncategorized | Leave a comment

Patent denied, price of prostate cancer drug may go down

The Indian Patent Office recently denied a patent for the drug Xtandi (Enzalutamide) by Japanese firm Astellas Pharma used in  treatment of prostate cancer. This decision comes in the light of the pre-grant opposition filed by pharma companies BDR Pharma, drug … Continue reading

Posted in Bayh Dole Act, March in rights, Patent, Patent Opposition, Sec 3 (d), Uncategorized | Tagged | Leave a comment

India to US: Will not tighten IPR rules beyond TRIPS mandate

Commerce Minister Nirmala Sitharaman demands food safety clearance mechanism during talks with US Trade Representative Source: The Hindu BusinessLine | October 20, 2016 India and the US continued to differ on the issue of intellectual property rights (IPR) norms at … Continue reading

Posted in Compulsory Licensing, Data Exclusivity, Evergreening, IPR, Patent linkage, Sec 3 (d), TRIPS, TRIPS plus, Uncategorized, UNHLP report, USTR 301 report | Leave a comment

Swamy & Subramanian: Comment and context

In a series of tweets, Swamy alleged that “Arvind Subramanian of Washington DC” had urged the US to act against India’s national interests, and called for him to be sacked. Source: The Indian Express | June 23, 2016 After having … Continue reading

Posted in Sec 3 (d), Uncategorized, USTR 301 report | Leave a comment

Hepatitis C sufferer warns ‘hundreds of thousands will die’ if India changes patent law in trade deal

By South Asia correspondent James Bennett, ABC News | Apr 2, 2016 India, sometimes dubbed “pharmacy to the developing world”, is facing pressure to change strict patent laws as it negotiates a trade deal with Europe. That would make it easier … Continue reading

Posted in EU-India FTA, FTA, Generics, Hepatitis C, Indian Patent Law, Uncategorized | Leave a comment

Govt. draws flak for decision to allow U.S.- trained patent examiners

By Vidya Krishnan, The Hindu | March 30, 2016 Humanitarian aid organisation Médecins Sans Frontières (Doctors Without Borders) has questioned the Indian government’s decision to have patent officers trained by the United States Patent & Trademark Office after the recent … Continue reading

Posted in Indian Patent Law, Patent examination system, Uncategorized | Leave a comment

Eli Lilly bats for a favourable patent regime in India

Eli Lilly wants a more favourable patent regime that ‘rewards innovation’ and would welcome an open dialogue from the government in this respect New Delhi: Global pharma company Eli Lilly wants a more favourable patent regime in India that “rewards … Continue reading

Posted in Indian Patent Law, Innovation, Special 301 report, Uncategorized | Leave a comment